Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy

Francesca Castagnoli¹*, Simon Doran², Jason Lunn², Anna Minchom³, Mary O’Brien⁴, Sanjay Popat⁵, Christina Messiou¹, Dow-Mu Koh¹

¹ Department of Radiology, Royal Marsden Hospital, Sutton, United Kingdom, ² Division of Radiotherapy and Imaging, Institute of Cancer Research, London, United Kingdom, ³ Drug Development Unit, Royal Marsden/Institute of Cancer Research, Sutton, United Kingdom, ⁴ Lung Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, United Kingdom, ⁵ Lung Unit, Royal Marsden Hospital/Institute of Cancer Research, London, United Kingdom

* francesca.castagnoli@rmh.nhs.uk

Abstract

Introduction

The spleen is a lymphoid organ and we hypothesize that clinical benefit to immunotherapy may present with an increase in splenic volume during treatment. The purpose of this study was to investigate whether changes in splenic volume could be observed in those showing clinical benefit versus those not showing clinical benefit to pembrolizumab treatment in non-small cell lung cancer (NSCLC) patients.

Materials and methods

In this study, 70 patients with locally advanced or metastatic NSCLC treated with pembrolizumab; and who underwent baseline CT scan within 2 weeks before treatment and follow-up CT within 3 months after commencing immunotherapy were retrospectively evaluated. The splenic volume on each CT was segmented manually by outlining the splenic contour on every image and the total volume summated. We compared the splenic volume in those achieving a clinical benefit and those not achieving clinical benefit, using non-parametric Wilcoxon signed-rank test. Clinical benefit was defined as stable disease or partial response lasting for greater than 24 weeks. A p-value of < 0.05 was considered statistically significant.

Results

There were 23 responders and 47 non-responders based on iRECIST criteria and 35 patients with clinical benefit and 35 without clinical benefit. There was no significant difference in the median pre-treatment volume (175 vs 187 cm³, p = 0.34), post-treatment volume (168 vs 167 cm³, p = 0.39) or change in splenic volume (-0.002 vs 0.0002 cm³, p = 0.97) between the two groups. No significant differences were also found between the splenic volume of patients with partial response, stable disease or progressive disease (p>0.017). Moreover, there was no statistically significant difference between progression-free survival.
and time to disease progression when the splenic volume was categorized as smaller or larger than the median pre-treatment or post-treatment volume (p>0.05).

Conclusion
No significant differences were observed in the splenic volume of those showing clinical benefit versus those without clinical benefit to pembrolizumab treatment in NSCLC patients. CT splenic volume cannot be used as a potentially simple biomarker of response to immunotherapy.

Introduction
Immunotherapy is one of the most important breakthroughs in cancer treatment, and, compared with standard therapies, immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) have been found to significantly prolong overall survival (OS) in patients with many different tumor types [1, 2]. Since the Food and Drug Administration (FDA) first approved PD-1 inhibitors in 2016 for the treatment of non-small cell lung cancer (NSCLC), pembrolizumab-based immunotherapy has been become standard of care [3–5].

Conventional chemotherapy has significant adverse effects on hematopoiesis and immunocompetence, altering the splenic niche and spleen volume [6–8]. For example, it was demonstrated that low dose administration of several chemotherapeutic agents such as gemcitabine and 5-fluorouracil can prevent the accumulation of myeloid derived suppressor cells (MDSCs) by restoring CD8+ T cells in the spleen [7]. Other studies recently proposed that the spleen can be used as a barometer of systemic immune response during immunotherapy as they observed that anti-programmed death-ligand 1 (PD-L1) treatment increased the percent population of monocytes/macrophages, CD8+ cells and natural killer cells in the spleen [9, 10]. It was also shown that highly dosed ipilimumab plus nivolumab resulted in increased proliferation of CD4+ and CD8+ lymphocytes as well as an increase of activated T cells and central memory T lymphocytes in the spleen which was accompanied by increased size of this organ [11].

Moreover, establishing better predictive markers for immunotherapy in lung cancer is a large unmet clinical need with tumoral PD-L1 (TPS) being an imperfect biomarker. In NSCLC patients with TPS of >50% the response rate to pembrolizumab is 44.8% and in NSCLC patients with PD-L1 <50% the response to pembrolizumab-chemotherapy combination is 56.7% [12, 13]. Therefore, using the current method of patient selection, around 50% of patients are expected to not respond to immunotherapy.

We hypothesize therefore, in patients without gross tumor infiltration of the spleen, changes in splenic volume during treatment may be correlated with alterations in the number and function of immune cells in the spleen. Although studies have investigated the correlation between the use of chemotherapy and the spleen volume [14, 15] and between immunotherapy and other types of tumour [16], to our knowledge, no reports have described the changing patterns of splenic size during immunotherapy in lung cancer patients, or their clinical significance. Therefore, the aim of our study was to investigate whether changes in splenic volume could be observed in patients that showed clinical benefit versus those who did not show clinical benefit to pembrolizumab treatment in patients with NSCLC.
Materials and methods

Study population
This retrospective study was approved by the institutional review board of the Royal Marsden Hospital. The requirement for written informed consent was waived. The inclusion criteria were as follows: (1) histologically proven NSCLC; (2) primary tumor with a minimum diameter >2cm; (3) no prior thoracic radiotherapy or surgery for the lung tumor; (4) underwent a baseline CT within 2 weeks before treatment and follow-up CT within 3 months after commencing immunotherapy.

We analyzed and divided the patients according to clinical benefit and iRECIST criteria [17]. Clinical benefit (CB) was defined as stable disease or partial response lasting for greater than 24 weeks, no clinical benefit as stable disease or partial response lasting less that 24 weeks or disease progression. Responders were defined as those showing a complete or partial response by iRECIST, while non-responders were defined as those showing stable or progressive disease at 12 weeks after therapy. For each patient, we also recorded their time to progression after initiating treatment, as well as time of death (if it occurred).

Computed tomography
Portal venous (PV) phase CE-CT were performed in all patients. All the CE-CT were performed at our institution using Siemens CT scanners (SOMATOM Definition Flash and SOMATOM Definition Edge; Siemens Healthcare, Erlangen, Germany). The thorax-abdomen CT were performed with iodine-based intravenous contrast (3–5 ml/second, total amount of 90–150ml, followed by bolus injection of 30cc normal saline) in portal-venous phase at 70 seconds delay. Images from all CT scanners were reconstructed at 3 mm slice thickness, which were used for splenic segmentation.

Measurement of splenic volume
The splenic volume was segmented manually on each CT by a radiologist (F.C. with 5 years of experience in abdominal imaging) using OHIF DICOM viewer on our XNAT research PACS system, by outlining the splenic contour on every relevant image and the total volume was summated using an offline Matlab script (Fig 1).

Statistical analysis
We compared the splenic volume in patients with and without clinical benefit; and between responders and non-responders using non-parametric Wilcoxon signed-rank test. Time to disease progression were calculated as the time from the start of treatment to disease recurrence/progression or death. Time to progression were compared in patients with clinical benefit to treatment versus those without benefit to treatment, as well as responders versus non-responders, stratified using the median pre-treatment splenic volume, post-treatment splenic volume and change in splenic volume using the Kaplan–Meier method. All statistical analyses were performed with MedCalc (version 12.1.0 for Microsoft Windows 2000/XP/Vista/7; MedCalc Software, Mariakerke, Belgium). A p-value less than 0.05 was considered statistically significant.

Results
Initially, 105 patients were identified; 29 patients were excluded due to lack of baseline imaging (n = 14) or follow-up scans (n = 15); 2 patients were excluded for suboptimal scan quality and 4 other patients were excluded due to lack of clinical follow-up. The remaining 70 patients
constituted our final study population. The included patients had irresectable/advanced stage NSCLC and received pembrolizumab between March 2019 and May 2020.

32 males and 38 females (median age = 68.71, range = 51–92 years) were enrolled. The majority (n = 69, 98.6%) had American Joint Committee on Cancer (AJCC) stage III or stage IV disease. The demographic and clinical characteristics of patients in this study are shown in Table 1.

**Table 1. Patient demographic and tumor characteristics.**

| Characteristics (N = 70) | Number | Percentage, % |
|-------------------------|--------|----------------|
| Age (median)            | 68.7   |                |
| Range                   | 51–92  |                |
| Sex (female/male)       | 38/32  |                |
| Histology               |        |                |
| Adenocarcinoma          | 56     | 80             |
| Squamous cell carcinoma | 10     | 14.3           |
| Mixed adenocarcinoma/squamous cell carcinoma | 1 | 4.3 |
| Carcinoma—other        | 3      | 1.4            |
| T stage                 |        |                |
| T1                      | 0      | 0              |
| T2                      | 1      | 1.4            |
| T3                      | 13     | 18.6           |
| T4                      | 56     | 80             |
| Regimen administered    |        |                |
| Pembrolizumab           | 59     | 84.3           |
| Pembrolizumab, carboplatin, pemetrexed | 11 | 15.7 |

https://doi.org/10.1371/journal.pone.0270950.t001

Fig 1. Representitive computed tomography (CT) images used to calculate spleen volume. Non-small cell lung cancer (*). Baseline axial CT scans and follow-up scans in a responder patient (A-D) and a non-responder (E-H).

https://doi.org/10.1371/journal.pone.0270950.g001
There were 1 complete response, 22 partial response, 23 stable disease and 24 progressive disease. There were 23 responders and 47 non-responders. Patients with stable disease or partial response lasting for greater than 24 weeks were deemed to have clinical benefit (n = 35) and the rest as without clinical benefit (n = 35).

**Splenic volume analyses before and after treatment**

Overall, the median splenic volume at baseline and at week 12 of pembrolizumab did not show any significant volume changes. After 3 months, the median spleen volume was 204 cm$^3$ (range: 42.5–455 cm$^3$) when compared with the baseline volume (201 cm$^3$ [39.6–467 cm$^3$ range]).

We found no significant difference in the median pre-treatment splenic volume (159 vs 192 cm$^3$, p = 0.36), post-treatment splenic volume (153 vs 169 cm$^3$, p = 0.35) or change in splenic volume (0 vs 0.0008 cm$^3$, p = 0.97) between patients with clinical benefit and those without clinical benefit (Fig 2). We also found no significant difference in the median pre-treatment splenic volume (175 vs 187 cm$^3$, p = 0.34), post-treatment splenic volume (168 vs 167 cm$^3$, p = 0.39) or change in splenic volume (-0.002 vs 0.0002 cm$^3$, p = 0.97) between responders and non-responders (Fig 3).

Moreover, there was no statistically significant difference in the median time to progression between patients with clinical benefit versus those without clinical benefit stratified by the median pre-treatment volume (12 months versus 11 months, p = 0.16), median post-treatment volume (14 months versus 10 months, p = 0.29) and median change in splenic volume (12 months versus 10 months, p = 0.18) (Fig 4).

---

![Fig 2. Splenic volume does not show significant changes in NSCLC patients with and without clinical benefit treated with pembrolizumab. The boxplots show the median spleen volume of NSCLC treated with pembrolizumab at baseline, after 12 weeks of treatment and the change in splenic volume between patients with and without clinical benefit.](https://doi.org/10.1371/journal.pone.0270950.g002)
There was also no statistically significant difference in the median time to progression between responders and non-responders stratified by the median pre-treatment volume (18 months versus 16 months, \( p = 0.68 \)), median post-treatment volume (16 months versus 25 months, \( p = 0.72 \)) and median change in splenic volume (17 months versus 16 months, \( p = 0.78 \)).

**Discussion**

Pembrolizumab is a PD-1 receptor inhibitors whose efficacy has been demonstrated in many clinical trials \([18–20]\). It has been approved for the treatment of NSCLC and melanoma by the FDA.

Monitoring the impact of immunotherapy on the spleen, an organ known to regulate hematopoiesis and immune responses \([21]\), is of interest in the context of appreciating the effects immunotherapy in NSCLC and other epithelial malignancies.

To our knowledge, this is first reported study that analyzed splenic size changes measured by 3-D volumetry as a potential indicator of alterations of the immune function during immunotherapy and its potential clinical significance. However, our study did not show any significant change in splenic volumetric during treatment with pembrolizumab, between the baseline measurement and follow-up measurement on CT, and hence there was no observable correlation with treatment outcomes.

Wen et al. \([15]\) reported early decrease in splenic volume after the commencement of platinum-based chemoradiotherapy in patients with localized advanced NSCLC. This could reflect immune-suppression as a consequence of treatment although the authors did not determine whether the splenic volume decrease was related to patient outcome or correlate it to the efficacy of chemotherapy. In particular, they found that a significant decrease in spleen volume was observed between baseline and Week 2 for patients treated with concomitant carboplatin/paclitaxel and cisplatin/etoposide and a further decrease occurred by Week 4 compared with...
baseline in the carboplatin/paclitaxel treatment group, whereas in patients treated with cisplatin/etoposide, the splenic volume returned to above baseline levels.

In contrast, Jung et al. [14] found that splenomegaly was observed in 67% of patients after 12 cycles of oxaliplatin-based chemotherapy; moreover, a sudden increase in splenic size was evident in some after 6 cycles of chemotherapy. However, the clinical significance of such splenic volume change remains uncertain.

Susok et al. [16] decided to investigate the effect of immunotherapy on spleen volume in patients with advanced melanoma. When compared with the baseline, they observed after 3 months a significant increase of median spleen volume under treatment with immune checkpoint inhibitors due to enhanced accumulation and proliferation of immune cells. The increase of spleen size observed in this study was significantly associated only with the use of ipilimumab and its combination with nivolumab.
Only a few studies have investigated the response of tumour types other than melanoma to immunotherapy with 18F-fluorodeoxyglucose positron emission tomography–computed tomography (18F-FDG PET/CT), especially non-small cell lung cancer, and some are case reports [22–27]. In a recent study assessing response of NSCLC to nivolumab [23], 24 patients were investigated at baseline and 1 month after the start of treatment. Response was determined using either morphological (RECIST 1.1) or PERCIST criteria, along with SUVmax, metabolic tumour volume (MTV) and total lesion glycolysis (TLG). Metabolic responses by 18F–FDG uptake (especially TLG) was associated with therapeutic response and survival at 1 month after nivolumab administration. However, they included a very small sample size and evaluated only early PET-CT. Metabolic splenic volume have not been reported specifically in the context of NSCLC and immunotherapy.

In this study, we hypothesize that treatment with pembrolizumab is associated with lymphocyte response, which could be reflected in changes in the splenic size. Studies have shown that pre-treatment lymphopenia or high neutrophil to lymphocyte ratio [28] is associated with shorter time to disease progression, while the development of lymphopenia during treatment has been observed with increased drug-related toxicity [29]. By contrast, NSCLC patients that showed significant response to pembrolizumab treatment has been reported to show a significant increase in the percentage of lymphocytes in the peripheral blood [30]. We theorize that the latter could be associated with an increase in splenic volume.

The lack of any significant splenic volume change in our study may be related to a number of factors. The first lies in the mechanism of action of pembrolizumab. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor that show high accumulation in organs such as the liver and spleen after administration [22, 31, 32]. It blocks the interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response, but may not have a significant effect on the splenic niche and structure. Second, peripheral lymphocytic expansion may not be associated with follicular expansion and splenic volume change. Indeed, in patients treated with platin-based chemotherapy, sinusoidal injury associated with such treatment has been associated with an increase in splenic size and is used as a secondary sign of liver damage [33, 34] rather than as a sign of treatment efficacy. Third, the splenic size is modulated by other factors such as physiological state and liver dysfunction, which may also occur in patients receiving pembrolizumab treatment.

There are limitations to this study. First, this study was retrospective. Nonetheless, this was a well-selected patient cohort with NSCLC and all received the same treatment. Second, the first CT follow-up available was at 12 weeks after commencing treatment and therefore we could not analyze any early changes in splenic volume.

**Conclusion**

Our study did not reveal any significant temporal changes in the human spleen volume during immunotherapy and that the spleen volume cannot be used to differentiate responders from non-responders in patients receiving pembrolizumab for NSCLC. Further work is being undertaken to elucidate whether the CT radiomics/textures of the splenic volume may provide additional insights to pembrolizumab immunotherapy response.

**Supporting information**

S1 Data.
(XLSX)
Acknowledgments
This study represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre and the Clinical Research Facilities (CRF) at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Author Contributions
Conceptualization: Francesca Castagnoli, Christina Messiou.
Data curation: Francesca Castagnoli, Anna Minchom, Mary O’Brien, Sanjay Popat.
Formal analysis: Simon Doran, Jason Lunn, Dow-Mu Koh.
Investigation: Francesca Castagnoli.
Methodology: Francesca Castagnoli, Anna Minchom.
Project administration: Dow-Mu Koh.
Software: Simon Doran, Jason Lunn.
Supervision: Christina Messiou, Dow-Mu Koh.
Writing – original draft: Francesca Castagnoli.
Writing – review & editing: Anna Minchom, Christina Messiou, Dow-Mu Koh.

References
1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018; 359 (6382):1350–5. https://doi.org/10.1126/science.aar4060 PMID: 29567705
2. Tang J, Yu JX, Hubbard-Lucey VM, Neftelinov ST, Hodge JP, Lin Y. Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug Discov. 2018; 17(12):854–5. https://doi.org/10.1038/nrd.2018.210 PMID: 30482962
3. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372(21):2018–28. https://doi.org/10.1056/NEJMoa1501824 PMID: 25891174
4. Reck M, Rodrı ´ guez-Abreu D, Robinson AG, Hui R, Csöszi T, Fülöp A, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol. 2019; 37(7):537–46. https://doi.org/10.1200/JCO.18.00149 PMID: 30620668
5. Gandhi L, Rodrı ´ guez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(22):2078–92. https://doi.org/10.1056/NEJMoa1801005 PMID: 29658856
6. Overman MJ, Maru DM, Charmsangavej C, Loyer EM, Wang H, Pathak P, et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010; 28(15):2549–55. https://doi.org/10.1200/JCO.2009.27.5701 PMID: 20406923
7. Ugel S, Peranzoni E, Desantis G, Chioda M, Walter S, Weinschenk T, et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep. 2012; 2(3):628–39. https://doi.org/10.1016/j.celrep.2012.08.006 PMID: 22959433
8. Germano G, Frapolli R, Belgiovin C, Anselmo A, Pesce S, Liguori M, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013; 23(2):249–62. https://doi.org/10.1016/j.ccr.2013.01.008 PMID: 23403077
9. Markel JE, Noore J, Emery EJ, Bobnar HJ, Kleinerman ES, Lindsey BA. Using the Spleen as an In Vivo Systemic Immune Barometer Alongside Osteosarcoma Disease Progression and Immunotherapy with α-PD-L1. Sarcoma. 2018; 2018:8694397. https://doi.org/10.1155/2018/8694397 PMID: 30651716
Knudson KM, Hicks KC, Alter S, Schlom J, Gameiro SR. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. J Immunother Cancer. 2019; 7(1):82. https://doi.org/10.1186/s40425-019-0551-y PMID: 30898149

11. Ji C, Roy MD, Golas J, Vitsky A, Ram S, Kumpf SW, et al. Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors. Clin Cancer Res 2019; 25(15):4735–48. https://doi.org/10.1158/1078-0432.CCR-18-4083 PMID: 31085720

12. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csáosi T, Fülöp A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823–33. https://doi.org/10.1056/NEJMoa1606774 PMID: 27718847

13. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Pataнак A, Powell SF, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016; 17 (11):1497–508. https://doi.org/10.1016/S1470-2045(16)30498-3 PMID: 27745820

14. Jung EJ, Ryu CG, Kim G, Kim SR, Park HS, Kim YJ, et al. Splenomegaly during oxaliplatin-based chemotherapy for colorectal carcinoma. Anticancer Res. 2012; 32(8):3357–62. PMID: 22843915

15. Wen SW, Everitt SJ, Bedő J, Chabrot M, Ball DL, Solomon B, et al. Spleen Volume Variation in Patients with Locally Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemoradiotherapy. PLoS One. 2015; 10(11):e0142608. https://doi.org/10.1371/journal.pone.0142608 PMID: 26959227

16. Susok L, Reinert D, Lukas C, Stockfleth E, Gambichler T. Volume increase of spleen in melanoma patients undergoing immune checkpoint blockade. Immunotherapy. 2021; 13(11):885–91. https://doi.org/10.2217/imm-2021-0022 PMID: 3429447

17. Seymor L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017; 18(3):e143–e52. https://doi.org/10.1016/S1470-2045(17)30074-8 PMID: 28271869

18. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007; 117(5):1137–46. https://doi.org/10.1172/JCI31405 PMID: 17476343

19. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006; 6(10):715–27. https://doi.org/10.1038/nri1936 PMID: 16977338

20. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016; 387(10027):1540–50. https://doi.org/10.1016/S0140-6736(15)01281-7 PMID: 26712084

21. Bronte V, Pittet MJ. The spleen in local and systemic regulation of immunity. Immunity. 2013; 39 (5):806–18. https://doi.org/10.1016/j.immuni.2013.10.010 PMID: 24238338

22. Wong A, Callahan J, Keyaerts M, Neyns B, Mangana J, Aberle S, et al. (18)F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. Cancer Imaging. 2020; 20(1):36. https://doi.org/10.1186/s40644-020-00313-2 PMID: 3208884

23. Kaira K, Higuchi T, Naruse I, Arisaka Y, Tokue A, Altan B, et al. Metabolic activity by (18)F-FDG PET/CT is predictive of early response after nivolumab in previously treated NSCLC. Eur J Nucl Med Mol Imaging. 2018; 45(1):56–66. https://doi.org/10.1007/s00259-017-3806-1 PMID: 28828507

24. Eshghi N, Lundeen TF, Kuo PH. Dynamic Adaptation of Tumor Immune Response With Nivolumab Demonstrated by 18F-FDG PET/CT. Clin Nucl Med. 2018; 43(2):114–6. https://doi.org/10.1097/RLU.0000000000001934 PMID: 29261621

25. Grizzli F, Castello A, Lopci E. Is it time to change our vision of tumor metabolism prior to immunotherapy? Eur J Nucl Med Mol Imaging. 45. 2018. p. 1072–5. https://doi.org/10.1007/s00259-018-3988-1 PMID: 29532102

26. Higuchi M, Owada Y, Inoue T, Watanabe Y, Yamaura T, Fukuhara M, et al. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer. World J Surg Oncol. 2016; 14(1):238. https://doi.org/10.1186/s12957-016-0998-y PMID: 27595749

27. Chardin D, Paquet M, Schiappa R, Darcourt J, Bailleux C, Poudenx M, et al. Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study. J Immunother Cancer. 2020; 8(2). https://doi.org/10.11186/jitc-2020-00065 PMID: 32709713

28. Brueckl WM, Ficker JH, Zeilinger C. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). BMC Cancer. 2020; 20 (1):1185. https://doi.org/10.1186/s12885-020-07690-8 PMID: 33272262

29. Diehl A, Yarchouan M, Hopkins A, Jaffee E, Grossman SA. Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1
checkpoint inhibitors. Oncotarget. 2017; 8(69):114268–80. https://doi.org/10.18632/oncotarget.23217 PMID: 29371985

30. Lee YJ, Park YS, Lee HW, Park TY, Lee JK, Heo EY. Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer. Sci Rep. 2022; 12(1):626. https://doi.org/10.1038/s41598-021-04630-9 PMID: 35022510

31. Cole EL, Kim J, Donnelly DJ, Smith RA, Cohen D, Lafont V, et al. Radiosynthesis and preclinical PET evaluation of (89)Zr-nivolumab (BMS-936558) in healthy non-human primates. Bioorg Med Chem. 2017; 25(20):5407–14. https://doi.org/10.1016/j.bmc.2017.07.066 PMID: 28803798

32. England CG, Ehlerding EB, Hernandez R, Rekoske BT, Graves SA, Sun H, et al. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab. J Nucl Med. 2017; 58(1):162–8. https://doi.org/10.2967/jnumed.116.177857 PMID: 27493273

33. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004; 15(3):460–6. https://doi.org/10.1093/annonc/mdh095 PMID: 14998849

34. Imai K, Emi Y, Iyama KI, Beppu T, Ogata Y, Kakeji Y, et al. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Eur J Surg Oncol. 2014; 40(5):559–66. https://doi.org/10.1016/j.ejso.2013.12.009 PMID: 24388740